UNICA IRIS Institutional Research Information System

FRAU, LUCIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 80.046
NA - Nord America 3.886
AS - Asia 1.485
SA - Sud America 180
Continente sconosciuto - Info sul continente non disponibili 162
AF - Africa 30
OC - Oceania 3
Totale 85.792
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 79.196
US - Stati Uniti d'America 3.827
SG - Singapore 581
CN - Cina 546
UA - Ucraina 257
SE - Svezia 193
BR - Brasile 141
VN - Vietnam 132
FI - Finlandia 93
DE - Germania 86
GB - Regno Unito 78
FR - Francia 62
HK - Hong Kong 55
IN - India 41
KR - Corea 32
CA - Canada 31
BD - Bangladesh 24
RU - Federazione Russa 19
PL - Polonia 12
AR - Argentina 11
IQ - Iraq 11
MX - Messico 11
NL - Olanda 11
ZA - Sudafrica 11
BE - Belgio 9
JP - Giappone 9
TR - Turchia 8
CZ - Repubblica Ceca 7
EC - Ecuador 7
CO - Colombia 6
EU - Europa 6
UZ - Uzbekistan 6
EG - Egitto 5
IR - Iran 5
JM - Giamaica 5
CL - Cile 4
ID - Indonesia 4
IE - Irlanda 4
KE - Kenya 4
NP - Nepal 4
AE - Emirati Arabi Uniti 3
AZ - Azerbaigian 3
BO - Bolivia 3
LT - Lituania 3
MA - Marocco 3
PE - Perù 3
RO - Romania 3
SA - Arabia Saudita 3
SV - El Salvador 3
TH - Thailandia 3
BB - Barbados 2
CH - Svizzera 2
CR - Costa Rica 2
ET - Etiopia 2
GR - Grecia 2
IL - Israele 2
JO - Giordania 2
KZ - Kazakistan 2
MN - Mongolia 2
NI - Nicaragua 2
NZ - Nuova Zelanda 2
PK - Pakistan 2
PY - Paraguay 2
VE - Venezuela 2
AU - Australia 1
BG - Bulgaria 1
BY - Bielorussia 1
CI - Costa d'Avorio 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
ES - Italia 1
GA - Gabon 1
HN - Honduras 1
HR - Croazia 1
KW - Kuwait 1
LU - Lussemburgo 1
MT - Malta 1
MY - Malesia 1
NG - Nigeria 1
NO - Norvegia 1
OM - Oman 1
PH - Filippine 1
PT - Portogallo 1
RS - Serbia 1
SY - Repubblica araba siriana 1
TN - Tunisia 1
TT - Trinidad e Tobago 1
UY - Uruguay 1
Totale 85.636
Salva come PNG Salva come JPEG
Città #
Cagliari 77.951
Uta 1.071
Ashburn 459
Singapore 316
Woodbridge 294
Fairfield 288
Chandler 264
San Jose 241
Ann Arbor 143
Jacksonville 141
Nyköping 136
Houston 133
Seattle 125
Wilmington 120
Boardman 117
Dallas 111
Dearborn 102
Beijing 98
Cambridge 98
Los Angeles 83
New York 79
Council Bluffs 58
Santa Clara 57
Helsinki 54
Hong Kong 43
Nanjing 40
Shanghai 37
Ho Chi Minh City 35
Lauterbourg 35
Boston 32
Hefei 32
Seoul 29
Guangzhou 26
Hanoi 25
Milan 24
Buffalo 22
Shenyang 20
The Dalles 20
Redwood City 19
San Diego 18
Dong Ket 16
Jinan 15
Toronto 15
Chicago 14
Hebei 13
Orem 13
Phoenix 13
São Paulo 13
Norwalk 12
Changsha 11
Jiaxing 11
Rome 11
Brooklyn 10
Mountain View 10
Munich 10
Brussels 9
Frankfurt am Main 9
Nanchang 9
Redondo Beach 9
Hangzhou 8
London 8
Orange 8
Dhaka 7
Düsseldorf 7
Montreal 7
Ningbo 7
Tianjin 7
Verona 7
Washington 7
Atlanta 6
Haiphong 6
Oristano 6
Padova 6
Tashkent 6
Warsaw 6
Wuhan 6
Zhengzhou 6
Amsterdam 5
Belo Horizonte 5
Columbus 5
Mexico City 5
Modrice 5
Pune 5
Rio de Janeiro 5
Tokyo 5
Baghdad 4
Campinas 4
Charlotte 4
Chengdu 4
Chennai 4
Da Nang 4
Gurgaon 4
Indore 4
Kathmandu 4
Kingston 4
Kunming 4
La Paz 4
Manchester 4
Nuremberg 4
Paris 4
Totale 83.440
Salva come PNG Salva come JPEG
Nome #
Widespread reduction of dopamine cell bodies and terminals in adult rats exposed to a low dose regimen of MDMA during adolescence 3.550
Rosiglitazone decreases peroxisome proliferator receptor-gamma levels in microglia and inhibits TNF-alpha production: new evidences on neuroprotection in a progressive Parkinson's disease model. 3.276
PPAR-gamma agonist rosiglitazone inhibits TNF-alpha production by microglia and arrests nigrostriatal degeneration in a progressive Parkinson’s disease model. 3.209
Antagonism of Adenosine A1 or A2A Receptors Amplifies the Effects of 3,4-Methylendioxymethamphetamine (MDMA) on Glial Activation in the Mouse Brain: Relevance to Caffeine-MDMA Interactions 3.153
A442 PPAR-gamma agonist rosiglitazone inhibits TNF-alpha production by microglia and arrests neurodegeneration in a progressive Parkinson´s disease model 3.061
Protective Agents in Parkinson's Disease: Caffeine and Adenosine A2A Receptor Antagonists 2.955
Direct and long-lasting effects elicited by repeated drug administration on 50-kHz ultrasonic vocalizations are regulated differently: Implications for the study of the affective properties of drugs of abuse 2.864
Late-onset Parkinsonism in NFκB/c-Rel-deficient mice 2.803
Effect of crowding, temperature and age on glia activation and dopaminergic neurotoxicity induced by MDMA in the mouse brain 2.746
MPTP-induced dopamine neuron degeneration and glia activation is potentiated in MDMA pretreated mice 2.727
Symptomatic and Neuroprotective Effects of A2A Receptor Antagonists in Parkinson’s Disease 2.699
Influence of caffeine on 3,4-methylenedioxymethamphetamine-induced dopaminergic neuron degeneration and neuroinflammation is age-dependent 2.695
Novel (Hetero)arylalkenyl propargylamine compounds are protective in toxin-induced models of Parkinson's disease 2.654
Microglial and astroglial activation by 3,4-methylenedioxymethamphetamine (MDMA) in mice depends on S(+) enantiomer and is associated with an increase in body temperature and motility 2.564
Disease modifying treatment with PPAR-gamma agonist rosiglitazone in a progressive mouse model of Parkinson's disease 2.521
Progressive Dopaminergic Degeneration in the Chronic MPTPp Mouse Model of Parkinson's Disease 2.441
Contribution of Caffeine to the Psychostimulant, Neuroinflammatory and Neurotoxic Effects of Amphetamine-Related Drugs 2.258
PPAR-gamma-mediated neuroprotection in a chronic mouse model of Parkinson's disease 2.256
Caffeine Enhances Astroglia and Microglia Reactivity Induced by 3,4-Methylenedioxymethamphetamine (‘Ecstasy’) in Mouse Brain 2.193
Performance of movement in hemiparkinsonian rats influences the modifications induced by dopamine agonists in striatal efferent dynorphinergic neurons 2.142
PPAR-GAMMA RECEPTOR AGONIST PREVENTS NEURODEGENERATION AND BEHAVIOURAL DEFICITS IN A CHRONIC MPTP MOUSE MODEL OF PARKINSON’S DISEASE. 2.123
Dyskinetic potential of dopamine agonists is associated with different striatonigral/striatopallidal zif-268 expression 2.112
Role of movement in long-term basal ganglia changes: implications for abnormal motor responses 1.982
PROGRESSIVE DECLINE OF BEHAVIORAL AND BIOCHEMICAL PARAMETERS IN THE CHRONIC MPTP/PROBENECID MOUSE MODEL OF PARKINSON’S DISEASE. 1.971
Alteration in the progression of dopamine neuron degeneration: May caffeine offer new perspective? 1.896
PEROXIZOME-PROLIFERATOR ACTIVATED RECEPTOR GAMMA (PPARG) AGONIST ROSIGLITAZONE COUNTERACTS BEHAVIORAL AND BIOCHEMICAL DEFICITS IN A CHRONIC 1-METHYL-4-PHENIL-1,2,3,4 TETRAHYDROPYRIDINE (MPTP) MOUSE MODEL OF PARKINSON’S DISEASE 1.895
Effect of adenosine A1 and A2A antagonists on 3,4 methylenedioxymethamphetamine (MDMA)-induced neuroinflammation and dopamine neuron toxicity in mouse brain 1.777
Neuroprotective and anti-inflammatory effects of the adenosine A(2A) receptor antagonist ST1535 in a MPTP mouse model of Parkinson's disease. 1.717
Behavioral and biochemical correlates of the dyskinetic potential of dopaminergic agonists in the 6-OHDA lesioned rat 1.677
null 1.651
Caffeine potentiation of 3,4-methylenedioxymethamphetamine (MDMA) toxicity: role of age 1.646
Effect of caffeine on 3,4- methylenedioxymethamphetamine-induced neuroinflammation in mouse brain 1.437
Characterization of the antiparkinsonian effects of the new adenosine A2A receptor antagonist ST1535: acute and subchronic studies in rats 1.304
Effect of caffeine on 3, 4 – methylenedioxymethamphetamine – induced astroglia and microglia activation in mouse brain 1.303
Direct and indirect striatal efferent pathways are differentially influenced by low and high dyskinetic drugs: behavioural and biochemical evidence 1.189
Caffeine potentiates 3,4 methylenedioxymethamphetamine (MDMA, ecstasy)-induced-glial activation: role of age and adenosine A1 and A2A receptors 1.119
Role of Adenosine A1 and A2A receptors on 3,4-methylendioxymeth-amphetamine (MDMA, Ecstasy)-induced neurotoxicity, astroglia and microglia reactivity in mouse striatum and substantia nigra 1.032
Protective Agents in Parkinson’s Disease: Caffeine and Adenosine A2A Receptor Antagonists 987
null 981
Behavioural and biochemical correlates of high and low dyskinetic parkinsonian drugs 576
Behavioural correlates of dopaminergic agonists dyskinetic potential in the 6-OHDA lesioned rat 348
Modulatory role of adenosine A(2A) receptors in basal ganglia as basis for the use of A(2A) antagonists in the treatment of Parkinson's disease 302
Totale 85.792
Salva come PNG Salva come JPEG
Categoria #
all - tutte 103.917
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 103.917
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20222.814 0 0 0 195 175 273 388 277 220 327 355 604
2022/20236.193 733 1.043 648 465 559 542 292 340 399 419 526 227
2023/20245.262 280 370 195 305 541 849 831 336 236 374 392 553
2024/20256.979 1.324 1.426 1.166 910 527 563 607 71 116 77 102 90
2025/20262.939 219 117 258 173 251 225 764 144 171 349 152 116
2026/2027791 92 119 282 298 0 0 0 0 0 0 0 0
Totale 85.792